NO20053748L - Pyrrolopyridazinderivater. - Google Patents

Pyrrolopyridazinderivater.

Info

Publication number
NO20053748L
NO20053748L NO20053748A NO20053748A NO20053748L NO 20053748 L NO20053748 L NO 20053748L NO 20053748 A NO20053748 A NO 20053748A NO 20053748 A NO20053748 A NO 20053748A NO 20053748 L NO20053748 L NO 20053748L
Authority
NO
Norway
Prior art keywords
pyrrolopyridazine derivatives
pyrrolopyridazine
derivatives
pde
tnf
Prior art date
Application number
NO20053748A
Other languages
English (en)
Norwegian (no)
Other versions
NO20053748D0 (no
Inventor
Kazuhiko Ohne
Yuki Sawada
Tsuyoshi Mizutani
Kenichiro Imamura
Yoshito Abe
Makoto Inoue
Kozo Sawada
Mitsuaki Okumura
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2003900189A external-priority patent/AU2003900189A0/en
Priority claimed from AU2003903628A external-priority patent/AU2003903628A0/en
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of NO20053748D0 publication Critical patent/NO20053748D0/no
Publication of NO20053748L publication Critical patent/NO20053748L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NO20053748A 2003-01-09 2005-08-04 Pyrrolopyridazinderivater. NO20053748L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2003900189A AU2003900189A0 (en) 2003-01-09 2003-01-09 Heterocyclic derivatives
AU2003903628A AU2003903628A0 (en) 2003-07-14 2003-07-14 Pyrrolopyridazine derivatives
PCT/JP2003/017091 WO2004063197A1 (fr) 2003-01-09 2003-12-26 Derives de pyrrolopyridazine

Publications (2)

Publication Number Publication Date
NO20053748D0 NO20053748D0 (no) 2005-08-04
NO20053748L true NO20053748L (no) 2005-10-07

Family

ID=32714072

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053748A NO20053748L (no) 2003-01-09 2005-08-04 Pyrrolopyridazinderivater.

Country Status (22)

Country Link
US (2) US7153854B2 (fr)
EP (1) EP1581535B3 (fr)
JP (1) JP4671104B2 (fr)
KR (1) KR101026819B1 (fr)
AR (1) AR042833A1 (fr)
AT (1) ATE376549T1 (fr)
BR (1) BR0317358A (fr)
CA (1) CA2513081C (fr)
CY (1) CY1107084T1 (fr)
DE (1) DE60317102T3 (fr)
DK (1) DK1581535T5 (fr)
ES (1) ES2291729T7 (fr)
HK (1) HK1088900A1 (fr)
IL (1) IL169500A0 (fr)
MX (1) MXPA05007462A (fr)
NO (1) NO20053748L (fr)
NZ (1) NZ541232A (fr)
PL (1) PL378245A1 (fr)
PT (1) PT1581535E (fr)
RU (1) RU2328499C2 (fr)
TW (1) TWI332004B (fr)
WO (1) WO2004063197A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4671104B2 (ja) 2003-01-09 2011-04-13 アステラス製薬株式会社 ピロロピリダジン誘導体
US7030112B2 (en) * 2003-03-25 2006-04-18 Bristol-Myers Squibb Company Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
WO2006004191A1 (fr) * 2004-07-05 2006-01-12 Astellas Pharma Inc. Derivés de pyrrolopyridazine qui inhibent la pde iv et le tnf alpha
ATE415400T1 (de) * 2004-07-05 2008-12-15 Astellas Pharma Inc Pyrazolopyridinderivate
GB0422057D0 (en) * 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
RU2009120389A (ru) 2006-10-30 2010-12-10 Новартис АГ (CH) Гетероциклические соединения в качестве противовоспалительных агентов
JP2009114123A (ja) * 2007-11-06 2009-05-28 Astellas Pharma Inc ２−アシル−１−アミノピロール化合物の新規製造法
EP2222639A1 (fr) 2007-11-21 2010-09-01 Decode Genetics EHF Inhibiteurs de biaryle pde4 pour le traitement de troubles pulmonaires et cardiovasculaires
WO2009087224A1 (fr) 2008-01-11 2009-07-16 Novartis Ag Pyrimidines utilisés en tant qu'inhibiteurs de kinase
US20110105510A1 (en) * 2008-06-17 2011-05-05 Hiroshi Ishikawa Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis
JP5731978B2 (ja) * 2008-09-26 2015-06-10 インテリカイン， エルエルシー 複素環キナーゼ阻害剤
WO2010059836A1 (fr) * 2008-11-20 2010-05-27 Decode Genetics Ehf Composés bicycliques substitués à pont aza pour maladie cardiovasculaire et du système nerveux central
EP3563842A1 (fr) 2009-04-29 2019-11-06 Amarin Pharmaceuticals Ireland Limited Compositions pharmaceutiques comprenant de l'epa et un agent cardiovasculaire et leurs procédés d'utilisation
US9387831B2 (en) * 2010-04-23 2016-07-12 Steam Tech, Llc Surface wiper system
EP2576561A1 (fr) * 2010-05-28 2013-04-10 Biocryst Pharmaceuticals, Inc. Composés hétérocycliques en tant qu'inhibiteurs de janus kinase
CN103097383B (zh) 2010-09-07 2015-09-16 安斯泰来制药株式会社 吡唑并喹啉化合物
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (fr) 2010-09-09 2012-03-15 Irm Llc Composés et compositions comme inhibiteurs de trk
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
MA34969B1 (fr) 2011-02-25 2014-03-01 Irm Llc Composes et compositions en tant qu inibiteurs de trk
JP5988941B2 (ja) * 2012-09-20 2016-09-07 富士フイルム株式会社 有機銅錯体、有機銅錯体溶液、銅酸化物薄膜、銅酸化物薄膜の製造方法、および、化合物
US10434132B2 (en) * 2013-06-04 2019-10-08 Academia Sinica Galactolipids-enriched plant extracts and the uses thereof
TWI695839B (zh) * 2017-11-17 2020-06-11 中央研究院 雙（羥甲基）吡咯并酞嗪混成物、其之製備方法與用途
JP7140915B2 (ja) * 2018-10-17 2022-09-21 スヴェン・ライフ・サイエンシーズ・リミテッド ムスカリンｍ１受容体陽性アロステリックモジュレーターとしてのピロロ－ピリダジン誘導体
CA3133100A1 (fr) 2019-03-19 2020-09-24 Boehringer Ingelheim Animal Health USA Inc. Composes d'aza-benzothiophene et d'aza-benzofurane anthelminthiques
JP2023528822A (ja) 2020-05-29 2023-07-06 ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド 駆虫性複素環式化合物
WO2023073641A1 (fr) 2021-11-01 2023-05-04 Boehringer Ingelheim Vetmedica Gmbh Composés de pyrrolopyridazine anthelminthiques

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991018903A1 (fr) * 1990-05-25 1991-12-12 Fujisawa Pharmaceutical Co., Ltd. Composes de pyrrolopyridazine
CA2332528A1 (fr) * 1998-05-21 1999-11-25 Shionogi & Co., Ltd. Inhibiteur spla2 pyrrolo[1,2-b] pyridazine
IT1303272B1 (it) * 1998-10-29 2000-11-06 Zambon Spa Derivati triciclici inibitori della fosfodiesterasi 4
FR2792938B1 (fr) * 1999-04-28 2001-07-06 Warner Lambert Co NOUVELLES 1-AMINO TRIAZOLO [4,3-a] QUINAZOLINE-5-ONES INHIBITRICES DE PHOSPHODIESTERASES IV
US7105550B2 (en) * 2000-03-01 2006-09-12 Christopher Love 2,4-disubstituted thiazolyl derivatives
AU2001267823A1 (en) * 2000-06-29 2002-01-08 Shionogi And Co., Ltd. Compounds exhibiting x-type spla2 inhibiting effect
JP2004522713A (ja) * 2000-11-17 2004-07-29 ブリストル−マイヤーズ　スクイブ　カンパニー ｐ３８キナーゼ関連疾患の処置方法およびキナーゼインヒビターとして有用なピロロトリアジン化合物
TWI312347B (en) * 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
US20040254189A1 (en) * 2001-08-23 2004-12-16 Hideaki Nagaya Jnk inhibitors
US6900208B2 (en) * 2002-03-28 2005-05-31 Bristol Myers Squibb Company Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
JP4671104B2 (ja) 2003-01-09 2011-04-13 アステラス製薬株式会社 ピロロピリダジン誘導体

Also Published As

Publication number Publication date
EP1581535A1 (fr) 2005-10-05
ATE376549T1 (de) 2007-11-15
DE60317102T2 (de) 2009-01-29
US20050075342A1 (en) 2005-04-07
TW200418861A (en) 2004-10-01
RU2005125209A (ru) 2006-01-27
NO20053748D0 (no) 2005-08-04
DK1581535T3 (da) 2008-02-11
US7317009B2 (en) 2008-01-08
PT1581535E (pt) 2007-12-12
CY1107084T1 (el) 2012-10-24
US7153854B2 (en) 2006-12-26
RU2328499C2 (ru) 2008-07-10
JP4671104B2 (ja) 2011-04-13
TWI332004B (en) 2010-10-21
US20060270678A1 (en) 2006-11-30
PL378245A1 (pl) 2006-03-20
DE60317102D1 (de) 2007-12-06
JP2006515597A (ja) 2006-06-01
CA2513081C (fr) 2011-04-19
KR101026819B1 (ko) 2011-04-04
DE60317102T3 (de) 2010-02-18
AR042833A1 (es) 2005-07-06
KR20050092738A (ko) 2005-09-22
BR0317358A (pt) 2005-12-13
WO2004063197A1 (fr) 2004-07-29
CA2513081A1 (fr) 2004-07-29
EP1581535B3 (fr) 2009-09-02
NZ541232A (en) 2008-02-29
MXPA05007462A (es) 2006-01-27
ES2291729T3 (es) 2008-03-01
EP1581535B9 (fr) 2008-03-19
EP1581535B1 (fr) 2007-10-24
HK1088900A1 (en) 2006-11-17
ES2291729T7 (es) 2010-03-31
DK1581535T5 (da) 2009-12-21
IL169500A0 (en) 2007-07-04

Similar Documents

Publication Publication Date Title
NO20053748L (no) Pyrrolopyridazinderivater.
NO20054905L (no) 2-acylamino-4-fenyltiazolderivater, fremgangsmate for deres fremstilling og anvendelse av de samme som i terapeutika
NO20081315L (no) Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser
NO20056010L (no) Biaryloksymetylaren-karboksylsyrer
NO20055421L (no) Kinolinderivater som fosfodiestrase-inhibitorer
NO20055887L (no) Pyrido'2, 1-A-isokinoliderivater som DPP-IV-inhibitorer
NO20064201L (no) Glukopyranosylsubstituerte benzolderivater, medikamenter inneholdende slike forbindelser, deres anvendelse og fremstilling
NO20072689L (no) Tetrasykliske indolderivater som antivirale midler
TW200606162A (en) Pyrazolopyridine derivatives
NO20062335L (no) Nye diazaspiroalkaner og deres anvendelse i behandlingen av CCR8 medierte sykdommer
NO20062020L (no) 1-amino-2-oksysubstituerte tetrahydronaftalenderivater, fremgangsmate for fremstilling derav, og deres anvendelse som antiflogistika
JO2353B1 (en) New derivatives of mixed-ring fluoroglycosides and drugs containing these compounds and their use
TNSN05194A1 (en) Substituted n-arylheterocycles, method for production and use thereof as medicaments
ATE378332T1 (de) Benzofuranderivate,verfahren zu deren herstellung und zwischenprodukte davon
NO20050088L (no) Kationisk substituerte difenylazefidinoner, fremgangsmate for deres fremstilling, medikamenter inneholdende nevnte forbindelser og anvendelse derav
CY1116885T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλομεθυλιου
NO20060147L (no) Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav
NO20050666L (no) 2,7-substituerte indoler og deres anvendelse som 5-HT6 modulatorer
NO20071137L (no) Nye piperidinderivater for behandling av depresjon
NO20082096L (no) Azaindol-2-karboksamidderivativer
DK1926729T3 (da) Benzothiazolcyclobutylaminderivater og deres anvendelse som histamin-3-receptorligander
NO20080394L (no) N-(arylalkyl)-1H-pyrrolopyridin-2-karboksamidderivater, fremstilling og anvendelse derav
NO20053809L (no) Diarylmetylindenpiperidinderivater,fremgangsmate for fremstilling derav, og anvendelse derav
NO20052699L (no) 4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gastrointestinale lidelser.
NO20063865L (no) Heterocyklisk substituerte 7-amino-4-kinolon-3-karboksylsyrederivater, fremgangsmate for fremstilling derav og deres anvendelse som medikamenter